For a polycythemia vera patient with symptomatic iron deficiency who is not currently undergoing phlebotomy to maintain hematocrit below 45 %, what iron supplementation regimen should be recommended?

Iron Supplementation in Polycythemia Vera with Symptomatic Iron Deficiency

For a polycythemia vera patient with symptomatic iron deficiency who is not currently undergoing phlebotomy, you should provide cautious iron supplementation to treat the documented severe tissue iron deficiency symptoms, while closely monitoring hematocrit levels and being prepared to initiate cytoreductive therapy if hematocrit rises unacceptably.

Clinical Context and Rationale

This scenario presents a unique challenge where two opposing principles collide: the general avoidance of iron supplementation in PV (to prevent dangerous hematocrit elevation) versus the need to treat symptomatic iron deficiency that impairs quality of life.

When Iron Supplementation is Indicated in PV

The most recent and relevant guideline 1 specifically addresses this situation, stating that "in the case of documented severe tissue iron deficiency associated with detrimental symptoms (pica, mouth paresthesia, esophagitis, restless legs), iron supplementation is indicated." Critically, this same guideline notes that "occurrence of undesired hematocrit worsening due to iron therapy indicates the need of cytoreduction."

This represents a conditional approach: iron can be given for symptomatic deficiency, but requires a safety net of cytoreductive therapy if hematocrit becomes problematic.

Specific Iron Supplementation Regimen

Oral Iron Protocol

• Start with ferrous sulfate 200 mg once daily (not twice daily as in typical iron deficiency) 2
• Consider every-other-day dosing initially, which may be better tolerated with similar absorption rates 2
• Add vitamin C 250-500 mg with the iron dose to enhance absorption 2, 3

Monitoring Requirements

Before starting iron:

• Document baseline hematocrit, hemoglobin, ferritin, and transferrin saturation
• Confirm symptomatic iron deficiency (not just laboratory values)

During iron supplementation:

• Check hematocrit weekly for the first month, then every 2 weeks
• Monitor ferritin and transferrin saturation monthly
• Assess symptom improvement (fatigue, pica, restless legs, paresthesias)

Critical Safety Thresholds

Hematocrit Management

The CYTO-PV trial 1 established that hematocrit must be maintained below 45% to minimize thrombotic risk. In your patient not currently on phlebotomy:

• If hematocrit rises to ≥45% during iron supplementation: Immediately initiate phlebotomy to bring hematocrit back below 45%
• If hematocrit rises to ≥50%: This represents inadequate control and requires cytoreductive therapy in addition to phlebotomy 1

When to Stop Iron and Start Cytoreduction

Initiate cytoreductive therapy (hydroxyurea or interferon) if:

• Hematocrit cannot be maintained <45% with phlebotomy alone after starting iron
• Patient requires frequent phlebotomy (≥3 in 6 months) to control hematocrit 1
• Symptomatic splenomegaly develops or worsens
• Platelet count rises >1500 × 10⁹/L or leukocyte count >15 × 10⁹/L 1

Alternative Approach: Intravenous Iron

While oral iron is the standard first-line approach, intravenous iron should be considered if:

• Oral iron is not tolerated despite every-other-day dosing 2
• No improvement in ferritin levels after 8 weeks of oral therapy 2
• Severe symptomatic iron deficiency requires rapid repletion

If using IV iron:

• Prefer single or two-infusion formulations (ferric carboxymaltose or iron dextran) 2, 3
• Maximum single dose: ferric carboxymaltose 1000 mg over 15 minutes 3
• Monitor hematocrit even more closely (every 3-5 days initially) as IV iron may cause more rapid hematocrit rise

Common Pitfalls to Avoid

1. Do not withhold iron indefinitely in symptomatic patients: The older dogma of absolute iron avoidance in PV 4 applies to hemochromatosis and asymptomatic PV patients, not those with documented symptomatic deficiency 1

2. Do not give iron without a monitoring plan: The combination of iron supplementation in PV without close hematocrit surveillance can lead to dangerous thrombotic complications 5, 6

3. Do not continue iron if hematocrit rises unacceptably: This is the key safety principle—iron is conditional on maintaining hematocrit control 1

4. Do not confuse microcytic polycythemia with hyperviscosity symptoms: Iron deficiency itself causes symptoms that mimic hyperviscosity (fatigue, headache) 7, 8. Treating the iron deficiency may actually improve symptoms without worsening viscosity 8

Duration of Iron Therapy

• Continue iron supplementation until symptoms resolve AND ferritin reaches >50 ng/mL 3
• Typical duration: 3-6 months
• After symptom resolution, discontinue iron to avoid unnecessary hematocrit elevation
• Resume low-dose iron only if symptomatic deficiency recurs

Long-term Management Strategy

Once symptomatic iron deficiency is corrected:

1. Reassess need for cytoreductive therapy based on thrombosis risk (age >60 or prior thrombosis) 1
2. If phlebotomy becomes necessary for hematocrit control, accept mild iron deficiency (ferritin 20-50 ng/mL) as tolerable 4
3. Reserve repeat iron supplementation only for recurrent severe symptomatic deficiency
4. Consider newer agents like hepcidin mimetics (rusfertide) in clinical trials, which may control hematocrit without causing iron deficiency 5